ClinicalTrials.gg
CompletedNCT06750289BRISOTEUpdated Oct 16, 2026

Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment

A Phase 3 interventional study of ICS-LABA and benralizumab in Eosinophilic Asthma, sponsored by AstraZeneca. Completed at 86 sites in 13 countries. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Updated Oct 16, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
12 Years to 75 Years
Sex
All
01

Study summary

This study evaluates the efficacy and safety of benralizumab as an add-on therapy in uncontrolled eosinophilic asthma participants treated with medium-dose ICS-LABA compared to the conventional treatment step of escalation of inhaled therapy to high-dose ICS-LABA.

Read the detailed description

This is a randomized, double-blind, active-controlled, parallel group global study designed to investigate the efficacy and safety of adding fixed-dose benralizumab (30 mg), administered subcutaneously (SC) every 4 weeks for the first 3 doses and then every 8 weeks for participants with a history of eosinophilic asthma, who remain uncontrolled on medium-dose Inhaled corticosteroid-Long-acting β2-agonists (ICS-LABA) with or without other asthma controller(s) (with the exception of oral corticosteroids), compared to the conventional treatment step of escalation of inhaled therapy to high-dose ICS-LABA plus placebo (benralizumab).

02

Conditions studied

  • Eosinophilic Asthma

Keywords

  • Eosinophilic Asthma;
  • Benralizumab,
  • FASENRA,
  • Medium-Dose Inhaled Corticosteroid,
  • Long-acting β2-Agonist
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • Participant must be 12 to 75 years of age
  • Documented history of physician-diagnosed asthma requiring treatment with at least medium-dose ICS (> 250 μg fluticasone dry powder formulation equivalents total daily dose) and a LABA, for at least 12 months prior to Visit (V) 1.
  • Documented treatment with medium-dose ICS and LABA for at least 3 months prior to Visit 1 with or without additional asthma controllers (excluding oral ).
  • Weight of ≥ 35 kg.
  • Pre-Bronchodilator (BD) (FEV1) of ≤ 90% predicted
  • Documented at least 2 asthma exacerbations in the 12 months prior to the date of informed consent.
  • ACQ-6 score ≥ 1.5 at Visit 1, plus at least once in the run-in period (from V2 to V3) and at V3.
  • Evidence of asthma as documented by excessive variability in lung function, as defined in the protocol.
  • Peripheral blood eosinophil count of ≥ 150 cells/μL, as defined in the protocol.
  • At least 70% compliance with usual asthma controller ICS-LABA during run-in period (from Visit 2 to Visit 3) based on asthma daily diary.

Exclusion criteria

Exclusion Criteria:

  • Important pulmonary disease other than asthma at the discretion of the investigator, or ever been diagnosed with pulmonary or systemic disease, other than asthma, which are associated with elevated peripheral eosinophil counts.
  • Asthma exacerbation requiring use of Systemic (SCS), or acute upper/lower respiratory infection that requires antibiotics or antiviral medication within 30 days prior to the date is obtained or during the screening/run-in period
  • Any unstable disorder that in the opinion of the investigator could affect the study according to the study protocol.
  • chronic or ongoing active infections requiring systemic treatment (at investigator's discretion)
  • Concurrent participation in another clinical study with an IP or a post-authorisation safety study.
  • History of alcohol or drug abuse within 12 months prior to the date informed consent is obtained.
  • Current smokers or former smokers with a smoking history ≥ 10 pack-years. Former smokers must have stopped for at least 6 months prior to Visit 1 to be eligible.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
130 participants (actual)

Study arms

  • Active comparator
    Medium-dose ICS-LABA + benralizumab

    Participants will be randomised 1:1 to one of the 2 study arms. Participants will receive up to 7 SC injections during study, with the first 3 doses administered every 4 weeks and then subsequent doses every 8 weeks.

    Combination Product: ICS-LABA · Combination Product: benralizumab

  • Active comparator
    High-dose ICS-LABA + placebo

    Participants will be randomised 1:1 to one of the 2 study arms. Participants will receive up to 7 SC injections during study, with the first 3 doses administered every 4 weeks and then subsequent doses every 8 weeks.

    Combination Product: ICS-LABA · Combination Product: Placebo for Benralizumab

Interventions

  • Combination productICS-LABA

    ICS-LABA inhalation

  • Combination productbenralizumab

    Benralizumab. SC injection.

  • Combination productPlacebo for Benralizumab

    Placebo for Benralizumab (aka, "placebo"). SC injection.

06

What researchers measure

Primary outcomes

  1. Annualized asthma exacerbation rate

    To assess asthma exacerbation rate.

    Time frame: Baseline through Week 48

Secondary outcomes

  1. Change in Saint George's Respiratory Questionnaire (SGRQ) total score

    The SGRQ is a 50-item ePRO instrument developed to measure the health status of participants with airway obstruction disease. The questionnaire is divided into 2 parts: Part 1 consists of 8 items that pertain to the severity of respiratory symptoms in the preceding 4 weeks, and Part 2 consists of 42 items related to the daily activity and psychosocial impacts of the individual's respiratory condition. The SGRQ yields a total score and 3 component scores (symptoms, activity, and impacts). The total score indicates the impact of disease on overall health status. This total score ranges from 0 to 100 with 0 indicating the best possible health status and 100 representing the worst possible health status

    Time frame: Baseline through Week 48

  2. Change in pre-bronchodilator FEV1

    Lung function is assessed by FEV1 which was measured by spirometry. Spirometry will be performed by the Investigator or authorized delegate according to American Thoracic Society /European Respiratory Society guidelines.

    Time frame: Baseline through Week 48

  3. Change in Asthma control questionnaire (ACQ) scale score.

    The ACQ-6 is a shortened version of the full 7-item ACQ questionnaire, which assesses asthma symptoms (nighttime awakening, symptoms on awakening, activity limitation, shortness of breath, wheezing, SABA use) but omits the FEV1 measurement from the original ACQ-7 assessment. Participants are asked to recall how their asthma has been during the previous week by responding to 6 symptom questions. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The total ACQ-6 score is the mean of the responses. The effect of benralizumab will be evaluated with the change from baseline in ACQ-6 to End of treatment (week 48) and over the treatment period.

    Time frame: Baseline through Week 48.

  4. Time to first asthma exacerbation

    Time to the first occurrence of asthma exacerbation post randomisation.

    Time frame: Baseline through Week 48.

  5. Annualized asthma exacerbation rate associated with an emergency/urgent care visit or a hospitalization

    The annualized exacerbation rate is based on unadjudicated exacerbation reported by the investigator that are associated with an emergency room/urgent care visit or a hospitalization adjusted by the time of follow-up.

    Time frame: Baseline through Week 48.

  6. Number and proportion of participants that meet each component of a 4-component clinical remission composite

    * Number and proportion of participants that meet each component of a 4-component clinical remission composite (no exacerbations; no mOCS use; ACQ-6 \< 1.5); and stable FEV1 (defined as change from baseline in FEV1 \> -100 mL) at Week 24 and EOT. * Number and proportion of participants that meet 0, 1, 2, 3 and all 4 components of the composite remission endpoint at Week 24 and EOT.

    Time frame: Week 24 and Week 48.

  7. Safety Adverse Event (AEs), Serious Adverse Event (SAEs), Adverse event leading to treatment discontinuation (DAEs.)

    Time frame: Baseline through Week 48.

07

Study locations

86 sites
  • Research Site
    Sun City, Arizona 85351, United States
  • Research Site
    Tucson, Arizona 85704, United States
  • Research Site
    Inglewood, California 90301, United States
  • Research Site
    Newport Beach, California 92663, United States
  • Research Site
    Pasadena, California 91101, United States
  • Research Site
    Cape Coral, Florida 33990, United States
  • Research Site
    Lauderdale Lakes, Florida 33313, United States
  • Research Site
    Leesburg, Florida 34748, United States
  • Research Site
    Miami, Florida 33175, United States
  • Research Site
    Tampa, Florida 33607, United States
  • Research Site
    Winter Park, Florida 32789, United States
  • Research Site
    Ann Arbor, Michigan 48109, United States
  • Research Site
    Henderson, Nevada 89052, United States
  • Research Site
    Northfield, New Jersey 08225, United States
  • Research Site
    New Hyde Park, New York 11042, United States
  • Research Site
    The Bronx, New York 10459, United States
  • Research Site
    DuBois, Pennsylvania 15801, United States
  • Research Site
    Warwick, Rhode Island 02886, United States
  • Research Site
    Greenville, South Carolina 29607, United States
  • Research Site
    San Antonio, Texas 78251, United States
  • Research Site
    Plovdiv, 4002, Bulgaria
  • Research Site
    Rousse, 7002, Bulgaria
  • Research Site
    Sofia, 1142, Bulgaria
  • Research Site
    Sofia, 1431, Bulgaria
  • Research Site
    Stara Zagora, 6000, Bulgaria
  • Research Site
    Kamloops, British Columbia V2C 5T1, Canada
  • Research Site
    Ajax, Ontario L1S 2J5, Canada
  • Research Site
    Toronto, Ontario M5T 3A9, Canada
  • Research Site
    Windsor, Ontario N8X 1T3, Canada
  • Research Site
    Beijing, 100044, China
  • Research Site
    Beijing, 102218, China
  • Research Site
    Changsha, 410004, China
  • Research Site
    Chongqing, 400042, China
  • Research Site
    Fuzhou, 350008, China
  • Research Site
    Guangzhou, 510120, China
  • Research Site
    Guangzhou, 510180, China
  • Research Site
    Hangzhou, 310014, China
  • Research Site
    Hefei, 230061, China
  • Research Site
    Huizhou, 516002, China
  • Research Site
    Jinan, 250021, China
  • Research Site
    Qinhuangdao, China
  • Research Site
    Shanghai, 200080, China
  • Research Site
    Shanghai, 200433, China
  • Research Site
    Wuhan, 430030, China
  • Research Site
    Xuzhou, 221000, China
  • Research Site
    Yinchuan, 750004, China
  • Research Site
    Zhengzhou, 450000, China
  • Research Site
    Créteil, 94010, France
  • Research Site
    Montpellier, 34295, France
  • Research Site
    Toulouse, 31059, France
  • Research Site
    Villeurbanne, 69100, France
  • Research Site
    Berlin, 10367, Germany
  • Research Site
    Berlin, 10717, Germany
  • Research Site
    Cottbus, 03050, Germany
  • Research Site
    Geesthacht, 21502, Germany
  • Research Site
    Lübeck, 23552, Germany
  • Research Site
    Wiesbaden, 65183, Germany
  • Research Site
    Shatin, 0000, Hong Kong
  • Research Site
    Cork, T12 DFK4, Ireland
  • Research Site
    Dublin, D15 X40D, Ireland
  • Research Site
    Moneymore, A92 VW28, Ireland
  • Research Site
    Bergamo, 24127, Italy
  • Research Site
    Genoa, 16132, Italy
  • Research Site
    Milan, 20122, Italy
  • Research Site
    Naples, 80131, Italy
  • Research Site
    Roma, 00161, Italy
  • Research Site
    Roma, 00168, Italy
  • Research Site
    Rozzano, 20089, Italy
  • Research Site
    Verona, 37124, Italy
  • Research Site
    Lørenskog, N-1478, Norway
  • Research Site
    Alcorcón, 28922, Spain
  • Research Site
    Badalona, 08916, Spain
  • Research Site
    Barakaldo, 48902, Spain
  • Research Site
    Jerez de la Frontera, 11407, Spain
  • Research Site
    Lugo, 27003, Spain
  • Research Site
    Madrid, 28034, Spain
  • Research Site
    Marbella, 29600, Spain
  • Research Site
    Marbella, 29603, Spain
  • Research Site
    Málaga, 29010, Spain
  • Research Site
    Palma de Mallorca, 7120, Spain
  • Research Site
    Santander, 39008, Spain
  • Research Site
    Aarau, 5001, Switzerland
  • Research Site
    Birmingham, B9 5SS, United Kingdom
  • Research Site
    Bradford, BD9 6RJ, United Kingdom
  • Research Site
    Bristol, BS10 5NB, United Kingdom
  • Research Site
    Leeds, LS9 7TF, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Mar 2025 to primary completion in Sep 2026, 17 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Nov 2028 → Sep 2026 and completion Nov 2028 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2024
First posted
Dec 27, 2024
StartActual
Mar 28, 2025
Primary completionActual
Sep 21, 2026was Nov 2028
CompletionActual
Sep 21, 2026was Nov 2028
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 16, 2026
Sites
74 sites removed
Show 74 removed
  • Research Site · Chandler, United States
  • Research Site · Bakersfield, United States
  • Research Site · Modesto, United States
  • Research Site · Denver, United States
  • Research Site · Hialeah, United States
  • Research Site · Miami, United States
  • Research Site · Miami, United States
  • Research Site · Orlando, United States
  • Research Site · Plantation, United States
  • Research Site · Union City, United States
  • Research Site · Oklahoma City, United States
  • Research Site · Oklahoma City, United States
  • Research Site · Houston, United States
  • Research Site · McKinney, United States
  • Research Site · Dimitrovgrad, Bulgaria
  • Research Site · Haskovo, Bulgaria
  • Research Site · Pleven, Bulgaria
  • Research Site · Plovdiv, Bulgaria
  • Research Site · Stara Zagora, Bulgaria
  • Research Site · Edmonton, Canada
  • Research Site · Vancouver, Canada
  • Research Site · Québec, Canada
  • Research Site · Sainte-Foy, Canada
  • Research Site · Beijing, China
  • Research Site · Fuzhou, China
  • Research Site · Fuzhou, China
  • Research Site · Hangzhou, China
  • Research Site · Linyi, China
  • Research Site · Ningbo, China
  • Research Site · Wenzhou, China
  • …and 44 more on the registry record
Oct 16, 2026
Primary completion
Nov 3, 2028→Sep 21, 2026 (actual)
Oct 16, 2026
Study completion
Nov 3, 2028→Sep 21, 2026 (actual)
Oct 16, 2026
Enrollment
400 (estimated)→130 (actual)
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Recruiting→Completed
    74 sites removed
    Show 74 removed
    • Research Site · Chandler, United States
    • Research Site · Bakersfield, United States
    • Research Site · Modesto, United States
    • Research Site · Denver, United States
    • Research Site · Hialeah, United States
    • Research Site · Miami, United States
    • Research Site · Miami, United States
    • Research Site · Orlando, United States
    • Research Site · Plantation, United States
    • Research Site · Union City, United States
    • Research Site · Oklahoma City, United States
    • Research Site · Oklahoma City, United States
    • Research Site · Houston, United States
    • Research Site · McKinney, United States
    • Research Site · Dimitrovgrad, Bulgaria
    • Research Site · Haskovo, Bulgaria
    • Research Site · Pleven, Bulgaria
    • Research Site · Plovdiv, Bulgaria
    • Research Site · Stara Zagora, Bulgaria
    • Research Site · Edmonton, Canada
    • Research Site · Vancouver, Canada
    • Research Site · Québec, Canada
    • Research Site · Sainte-Foy, Canada
    • Research Site · Beijing, China
    • Research Site · Fuzhou, China
    • Research Site · Fuzhou, China
    • Research Site · Hangzhou, China
    • Research Site · Linyi, China
    • Research Site · Ningbo, China
    • Research Site · Wenzhou, China
    • …and 44 more on the registry record
    Primary completion Nov 3, 2028→Sep 21, 2026 (now actual)
    Study completion Nov 3, 2028→Sep 21, 2026 (now actual)
    Enrollment 400 (estimated)→130 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06750289
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Dec 27, 2024
Start date
Mar 28, 2025
Primary completion
Sep 21, 2026
Completion
Sep 21, 2026
Last update
Oct 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benralizumab

Start the discussion